Due to scheduled maintenance work, this service may not be available on Monday January 22nd between 08.00 am and 9.00 am CEST.
To improve security and privacy, we are moving our web pages and services from HTTP to HTTPS.
To give users of web services time to transition to HTTPS, we will support separate HTTP and HTTPS services until the end of 2017.
From January 2018 most HTTP traffic will be automatically redirected to HTTPS. [more...]
View this page in https
PROSITE documentation PDOC00204 [for PROSITE entry PS00319]

Amyloidogenic glycoprotein signatures


Amyloidogenic glycoprotein (A4 protein or APP) is an integral, glycosylated membrane brain protein [1,2]. APP is associated with Alzheimer's disease (AD). This responsibility stems from the fact that a small peptide (of 43 residues), called the amyloid β protein, which is part of the sequence of A4, is the major constituent of amyloid deposits in AD and in Down's syndrome. As shown in the schematic representation below, the amyloid β protein both precedes and forms part of the unique transmembrane region of A4.

       |  Extracellular                         XXXXXXX Cytoplasmic |
'X': Transmembrane region.
'B': Position of the amyloid beta protein in A4.

The exact function of A4 protein is not yet known, but it has been suggested that it mediates cell-cell interactions. The sequence of A4 from mammalian species is well conserved and is also similar to that of other proteins:

  • Drosophila APPL (gene vnd) [3].
  • Mammalian protein APLP1 [4].
  • Mammalian protein APLP2 (APPH) (YWK-II) (CDEI-binding protein) [5].

We have derived two patterns specific to these proteins, the first one is a perfectly conserved octapeptide located in the beginning of the extracellular domain; the second is a conserved octapeptide located at the C-terminal end of the cytoplasmic domain.

Last update:

December 2004 / Pattern and text revised.

Technical section

PROSITE methods (with tools and information) covered by this documentation:

A4_EXTRA, PS00319; Amyloidogenic glycoprotein extracellular domain signature  (PATTERN)

A4_INTRA, PS00320; Amyloidogenic glycoprotein intracellular domain signature  (PATTERN)


1AuthorsDyrks T., Weidemann A., Multhaup G., Salbaum J.M., Lemaire H.-G., Kang J., Muller-Hill B., Masters C.L., Beyreuther K.
TitleIdentification, transmembrane orientation and biogenesis of the amyloid A4 precursor of Alzheimer's disease.
SourceEMBO J. 7:949-957(1988).
PubMed ID2900137

2AuthorsAshall F., Goate A.M.
TitleRole of the beta-amyloid precursor protein in Alzheimer's disease.
SourceTrends Biochem. Sci. 19:42-46(1994).
PubMed ID8140621

3AuthorsRosen D.R., Martin-Morris L., Luo L.Q., White K.
TitleA Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor.
SourceProc. Natl. Acad. Sci. U.S.A. 86:2478-2482(1989).
PubMed ID2494667

4AuthorsWasco W., Bupp K., Magendantz M., Gusella J.F., Tanzi R.E., Solomon F.
TitleIdentification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor.
SourceProc. Natl. Acad. Sci. U.S.A. 89:10758-10762(1992).
PubMed ID1279693

5AuthorsSprecher C.A., Grant F.J., Grimm G., O'Hara P.J., Norris F., Norris K., Foster D.C.
TitleMolecular cloning of the cDNA for a human amyloid precursor protein homolog: evidence for a multigene family.
SourceBiochemistry 32:4481-4486(1993).
PubMed ID8485127

PROSITE is copyright. It is produced by the SIB Swiss Institute Bioinformatics. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified. Usage by and for commercial entities requires a license agreement. For information about the licensing scheme send an email to
Prosite License or see: prosite_license.html.


View entry in original PROSITE document format
View entry in raw text format (no links)